Skip to main content
Sign In

Resources For: Prospective Students | Current Students | Parents | Faculty & Staff | Alumni & Friends | Patients

 

Thomas B. Campbell, MD

Professor, Interim Head, Division of Infectious Diseases
 
 

Phone:     303-724-4922
E-mail:     Thomas.Campbell@ucdenver.edu
Address:   B168

Medical School
Southwestern Medical school, Dallas TX

Residency
Parkland Memorial Hospital, Dallas TX

Fellowship
University of Colorado Denver

Postdoctoral Fellowship
Department of Chemistry and Biochemistry at University of Colorado, Boulder, CO

 

I conduct research to improve the treatment of HIV infection and AIDS-related complications. As Principal Investigator of the Colorado AIDS Clinical Trials Unit I conduct research to optimize the clinical management of HIV-1 infection including the development of improved strategies for administration of antiretroviral therapy, improved management of treatment-related toxicities, and better treatment of multi-drug resistant HIV-1 infection. I am the lead investigator of the first comparative study of antiretroviral efficacy and safety in resource-limited settings around the world. I am Director of the Colorado HIV Research Training Program, which provides support for postdoctoral training in AIDS research at UCD and affiliated institutions. I am Director of the Colorado Center for AIDS Research Virology Core Laboratory, which makes virology tools and services available to University of Colorado investigators for research in AIDS pathogenesis and treatment. I am Associate Program Director of the Colorado Adult General Clinical Research Center, a state-of-the-art facility available to Colorado medical investigators to conduct safe, controlled, inpatient and outpatient studies of humans.

 

1) Campbell TB, Staskus KA, Folkvord J, White IE, Neid J, Zhang X-Q, Connick E. Persistence of Kaposi's sarcoma-associated herpesvirus (KSHV) infected cells in HIV-1 co-infected persons without KSHV-associated diseases. J Infect Dis 2005; 191:367-371.

2) Flanigan TP, Campbell T, Harwell J, and Kumarasamy N. The extraordinary hope of antiretroviral therapy in South Africa (Even for patients with tuberculosis or Kaposi sarcoma!). J Infect Dis 2005;191:321-323.

3) Campbell TB, Katzenstein D. Antiretroviral Rounds. Resistance: How do you know if you don't know?. Antiretroviral Rounds. AIDS Clin Care 2005;17.

4) Connick E, MaWhinney S, Wilson CC, Campbell TB. Challenges in the study of HIV-1 seroconverters. Clin Infect Dis 2005;40:1355-1357.

5) Campbell TB, Shulman N, Johnson SC, Zolopa AR, Young RK, Bushman L, Fletcher CV, Lanier ER, Merigan T, Kuritzkes DR. Antiviral activity of lamivudine in salvage therapy of multidrug-resistant human immunodeficiency virus type 1 infection. Clin Infect Dis 2005;41:236-242.

6) Campbell TB. Are all HIV-1 created equal? Clin Infect Dis 2006;42:853-854.

7) Koeppe JR, Campbell TB, Rapaport EL, Wilson CC. HIV-1 specific CD4+ T cell responses are not associated with significant viral epitope variation in persons with persistent plasma viremia. J Acquir Immune Defic Syndr. 2006;41:140-148.

8) Barbour JD, Hecht FM, Little SJ, Markowitz M, Daar ES, Kellecher AD, Kaldor J, Routh JP, Campbell TB, Rosenberg E, Schafer K, Wood K, Weidler J, Bates M, Grant RM. Greater CD4+ T cell responses during antiretroviral therapy associates with lower viral pol replication capacity. AIDS 2006;20:2123-2125.

9) Gripshover B, Santana J, Ribaudo H, Gerber J, Campbell TB, Hogg E, Jarocki B, Hammer S, and Kuritzkes D. A randomized, placebo-controlled trial of amdoxovir vs placebo with enfuvirtide plus optimized background therapy for HIV-infected subjects failing current therapy (AACTG 5118). Antiviral Therapy (in press)

10) Meditz AL, Borok M, Gudza I, Ndemera B, Gwanzura L, Campbell TB. Sex Differences in AIDS-associated Kaposi's Sarcoma in Zimbabwe. J Acquir Immune Def Syndr (in press).

11) Boritz E, Rapaport E, Campbell TB, Koeppe JR, Wilson CC. CD4+ T Cell Targeting of HIV-1 peptide sequences present in vivo during chronic, progressive HIV-1 disease. Virology (in press).

 

 

NIH P30 AI054907 University of Colorado Center for AIDS Research (CFAR) Virology Core

IH PO1 AI055356 "Immunopathogenesis of Acute HIV-1 Infection", Project 5, "Role of Fitness of Transmitted Virus"